86 studies found for:    chelation AND heart
Show Display Options
Rank Status Study
1 Completed
Has Results
Trial to Assess Chelation Therapy (TACT)
Condition: Coronary Artery Disease
Interventions: Drug: EDTA;   Drug: EDTA Placebo;   Dietary Supplement: High Dose Vitamin;   Dietary Supplement: High Dose Vitamin Placebo
2 Completed Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major
Conditions: Iron Overload;   Cardiomyopathy
Interventions: Drug: Deferoxamine and Deferiprone;   Drug: Deferoxamine
3 Recruiting An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)
Condition: Thalassemia, Non-transfusion Dependent Thalassemia, Myelodysplastic Syndromes, Myelofibrosis, Other Anemia
Intervention: Radiation: Single arm MRI test
4 Recruiting Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload
Conditions: Transfusion-dependent β-thalassemia Patients;   Cardiac Iron Overload
Interventions: Drug: Deferasirox;   Drug: Deferasirox + Deferoxamine
5 Completed Efficacy Study in Removing Excess Iron From the Heart
Conditions: Thalassemia Major;   Hemosiderosis
Interventions: Drug: Ferriprox (deferiprone);   Drug: Desferal (deferoxamine)
6 Recruiting Amlodipine for Myocardial Iron in Thalassemia
Condition: Thalassemia
Interventions: Drug: Deferasirox or Deferoxamine or Combination (Deferoxamine and Deferiprone);   Drug: Amlodipine
7 Active, not recruiting Cardiac Function in Patients With Hereditary Hemochromatosis
Condition: Hemochromatosis
Intervention:
8 Recruiting Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia
Condition: Thalassemia Major With Severe Transfusional Iron Overload
Intervention: Drug: Deferasirox and deferiprone
9 Completed Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment
Conditions: Beta-thalassemia;   Iron Overload
Intervention: Drug: Deferasirox
10 Unknown  Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major
Condition: Beta-Thalassemia
Intervention: Drug: deferiprone
11 Completed Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload
Conditions: Transfusional Iron Overload;   Transfusional Hemosiderosis
Interventions: Drug: Core Study: Deferasirox;   Drug: Core Study: Deferoxamine;   Drug: Extension: deferoxamine to deferasirox;   Drug: Extension: deferasirox to deferoxamine;   Drug: Deferasirox;   Drug: Deferoxamine
12 Unknown  Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent
Condition: Acute Kidney Injury
Interventions: Drug: deferiprone;   Drug: Placebo
13 Unknown  Clinical Importance of Treating Iron Overload in Sickle Cell Disease
Conditions: Anemia, Sickle Cell;   Transfusion Hemochromatosis
Intervention: Drug: deferasirox
14 Unknown  Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both
Condition: Thalassemia
Interventions: Drug: Deferoxamine;   Drug: Deferasirox
15 Recruiting Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
Conditions: Hemochromatosis;   Myelodysplastic Syndromes
Interventions: Drug: Deferasirox;   Other: Venesection
16 Completed Combo Chelation Trial
Conditions: Thalassemia;   Iron Overload
Intervention: Drug: Combo Chelation with Deferasirox (Exjade) and Desferal (DFO)
17 Completed Efficacy of EVP 1001-1 (SeeMore) in the Assessment of Myocardial Viability in Patients With Cardiovascular Disease
Condition: ISCHEMIC CARDIOMYOPATHY
Intervention: Drug: 'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT
18 Completed Efficacy Study of the Use of Sequential DFP-DFO Versus DFP
Conditions: Beta-Thalassemia;   Thalassemia Major
Interventions: Drug: Deferiprone (DFP) and Deferoxamine (DFO);   Drug: Deferiprone (DFP)
19 Completed MR Imaging of Diffuse Myocardial Fibrosis in Transfusion-Dependent Anemias
Conditions: Thalassemia Major;   Chronic Blood Transfusion Related Iron Overload
Intervention:
20 Completed Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload
Conditions: Transfusional Iron Overload;   Beta-thalassemia
Intervention: Drug: SPD602 (FBS0701, SSP-004184)

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years